Intensified adjuvant cyclophosphamide, methotrexate and 5-fluorouracil therapy: A dose-finding study for ambulatory patients with breast cancer

Oncology

Volumn 56, Issue 2, 1999, Pages 103-109

  Hietanen, Päivi ^a   Teerenhovi, L ^a   Joensuu, H ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

5 Fluorouracil; Adjuvant therapy; Breast cancer; Cyclophosphamide; Dose intensity; Methotrexate

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; MESNA; METHOTREXATE; OFLOXACIN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLADDER IRRITATION; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CONSTIPATION; CYSTITIS; DIARRHEA; DOSE CALCULATION; ERYTHEMA; EYE IRRITATION; FEMALE; FEVER; GRANULOCYTOPENIA; HOSPITALIZATION; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MAXIMUM PERMISSIBLE DOSE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; SKIN EDEMA; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AGRANULOCYTOSIS; ALOPECIA; AMBULATORY CARE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CONJUNCTIVITIS; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; GASTROINTESTINAL DISEASES; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; METHOTREXATE; MIDDLE AGED; NEUTROPENIA; TREATMENT OUTCOME; URINARY BLADDER;

EID: 0033062671     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000011948     Document Type: Article

References (15)

1. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. N Engl J Med 1995;332: 901-906.
2. Carpenter JT, Valez-Garcia E, Aron BS, Salter M, Stahl DL, Estes N, Stagg M, Bartolucci A, Singh KP, Birmingham AI: Five-year results of a randomized comparison of cyclophosphamide, doxorubicin (Adriamycin) and fluorouracil (CAF) vs. cyclophosphamide, methotrexate and fluorouracil (CMF) for node positive breast cancer: A Southeastern Cancer Study Group Study. Proc Am Soc Clin Oncol 1994; 13:A68.
3. Coombes RC, Bliss JM, Morvan F, Espié M, Amadori D, Gambrosier P, Richards M, Aapro M, Villat-Grimalt A, McArdle C, Pérez-López FR, Vassilopoulos P, Ferreira P, Chilvers CED, Coombes G, Woods EM, Marty M: Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: Results of a randomized trial. J Clin Oncol 1996;14:35-45.
4. Moliterni A, Bonadonna G, Vaagussa P, Ferrari L, Zambetti M: Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes. J Clin Oncol 1991;9:1124-1130.
5. Bonadonna G, Zambetti M, Valagussa P: Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 1995; 273:542-547.
6. De Bruijn EA, Slee PTTh, Van Oosterom AT: Pharmacokinetics of intravenous and oral cyclophosphamide in the presence of methotrexate and fluorouracil. Pharm Weekbl 1988;10: 200-206.
7. Wood WC, Budraan DR, Korzun AH, Cooper R, Younger J, Hart RD, Moore A, Ellerton JA, Norton L, Ferree CR, Ballow AC, Frei E III, Henderson IC: Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994;330: 1253-1259.
8. Engelsman E, Klijn JC, Rubens RD, Wildiers J, Beex LVAM, Nooij MA, Rotmensz N, Sylvester R: 'Classical' CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-Operative Group Phase III Trial (10808). Eur J Cancer 1991;27: 966-970.
9. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication. Geneva, WHO, 1979.
10. Kupperman HS, Blatt MHG, Wiesbader H, Filler W: Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. Endocrinology 1953;13: 688-703.
11. Wiklund I, Berg G, Hammar M, Karlberg J, Lindgren R. Sandin K: Long- term effect of transdermal hormonal therapy on aspects of quality of life in postmenopausal women. Maturitas 1992;14:225-236.
12. Fisher B, Anderson S, Wickerham DL, DeCillis A, Dimitrov N, Mamounas E, Wolmark N, Pugh R, Atkins JN, Meyers FJ, Abramson N, Wolter J, Bornstein RS, Levy L, Romond EH, Caggiano V, Grimaldi M, Jochimsen P, Deckers P: Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 1997;15:1858-1869.
13. Antman K, Ayash L, Elias A, Wheeler C, Hunt M, Eder JP. Teicher BA, Critchlow J, Bibbo J, Schnipper LE, Frei E: A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992;10:102-110.
14. Peters WP, Ross M, Vredenburgh, Meisenberg B, Marks LB, Winer E, Kurzberg J, Bast RC, Jones R, Shpall E, Wu K, Rosner G, Gilbert C, Mathias B, Coniglio D, Petros W, Henderson IC, Norton L, Weiss RB, Budman D, Hurd D: High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993;11: 1132-1143.
15. Swain SM, Rowland J, Weinfurt K, Berg Christine, Lippman ME, Wallon L, Egan E, King D, Spertus I, Honig SF: Intensive outpatient adjuvant therapy for breast cancer: Results of dose escalation and quality of life. J Clin Oncol 1996;14:1565-1572.